<DOC>
	<DOC>NCT01946711</DOC>
	<brief_summary>The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.</brief_summary>
	<brief_title>Buparid/PARI SINUS Versus BudesÂ® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi grade IIII Patient with a PNIF of &gt; 7 l/min separated for left and right side of the nose Patient's written informed consent Male or female,&gt;= 18 years of age Patient is able to undergo nasal therapy without restrictions Capable of understanding the purpose and risk of the clinical trial Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration Patient has completed correctly the diary during the Washin Phase Patients with cystic fibrosis Patients with polyposis nasi grade IV Patients with prior sinonasal surgery (exemption: polypectomy) Patients with primary ciliaritis Pregnant or breastfeeding women Patients with suspected active upper airway infection Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP Drug or alcohol abuse Endstage malignancies Known hypersensitivity to Budesonide Patients with oral steroid therapy within the last 4 weeks Patients with frequent epistaxis (&gt; 2 per month)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CRS</keyword>
	<keyword>polyposis</keyword>
</DOC>